
|Videos|January 12, 2022
Urology Times 50 Innovations Series: Testosterone therapy
Author(s)Urology Times staff
"This field has exploded!" says Mohit Khera, MD, MBA, MPH.
Advertisement
As part of the Urology Times' 50th Anniversary Innovation Celebration, Amy Pearlman, MD, interviewed Mohit Khera, MD, MBA, MPH, on how testosterone therapy has greatly impacted the field of urology over the past 50 years. Khera is a professor of urology and director of the Laboratory for Andrology Research, and director of the Executive Health Program at the McNair Medical Institute at Baylor College of Medicine in Houston, Texas. Pearlman is a clinical assistant professor of urology and the director of the Men’s Health Program at the Carver College of Medicine at University of Iowa Health Care in Iowa City, Iowa.
Advertisement
Related to this article

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.

Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Advertisement
Advertisement
Trending on Urology Times
1
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5








































